BCDA - BioCardia Company Cash Volume

Symbol and logo of brand BioCardia (BCDA)

BioCardia, Inc. (BCDA) is facing a liquidity shortage due to costly clinical trials; however, its intellectual capital in cell therapy will secure future patent profits. The innovative Helix system enables the restoration of a patient's heart using their own cells. This cash liquidity chart illustrates account balances, where the 0.00 mark serves as the key metric for assessing the company's current cash reserves.

BioCardia Inc. - BCDA Company Liquid Assets (period 07/04/2022 - 11/21/2026)

Metric breakdowns and analytics for BioCardia (BCDA)

- stock value and consensus price forecast:
Summary company analytics:BioCardia Inc
Brand item of biocardia.com

BioCardia, Inc. (BCDA) maintains a strong position in the regenerative cardiology segment thanks to its unique staff of biochemists. This indicator measures the volume of liquid assets, determining the issuer's ability to fund R&D without resorting to external loans. Investors view this balance as a guarantee of autonomy when hiring regulatory compliance specialists. Changes in the size of cash balances demonstrate the rate of capital burn. This price action reflects the efficiency of resource management.